RM
Richard Murray
Director

Richard Murray insider trades: Jounce Therapeutics (JNCE) stock sales

Director, Jounce Therapeutics Last trade Apr 4, 2023 31 Form 4 filings
$0
Sold, last 12 months
0 sales
$0
Bought, last 12 months
0 buys
14
Open-market trades
since 2005
2
Companies
last trade 2023

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Richard reports to the SEC

Open-market buys and sales

14 trades reported on SEC Form 4, newest first

DateStockTypeValue
Apr 4, 2023JNCE↓ Sell$73K
Jan 10, 2023JNCE↓ Sell$50K
Jan 10, 2022JNCE↓ Sell$257K
Jan 21, 2021JNCE↓ Sell$404K
Jan 20, 2021JNCE↓ Sell$838K
Jan 8, 2021JNCE↓ Sell$152K
Jan 7, 2020JNCE↓ Sell$56K
Dec 23, 2019JNCE↓ Sell$335K
Mar 8, 2018JNCE↓ Sell$410K
Mar 5, 2018JNCE↓ Sell$350K
Mar 6, 2006PDLI↓ Sell$480K
Sep 6, 2005PDLI↓ Sell$288K
Aug 3, 2005PDLI↓ Sell$829K
Jun 20, 2005PDLI↓ Sell$420K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

About Richard Murray's insider trades

Richard Murray is a director at Jounce Therapeutics (JNCE). Since Jun 20, 2005, Richard has reported no open-market purchases and 14 sales worth $4.9M on SEC Form 4. There have been no open-market trades in the last 12 months.

Their filings also include option exercises (11 filings), grants and awards (9 filings), shares withheld for taxes (5 filings), shares returned to the company (1 filing). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every JNCE insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.